Literature DB >> 16260051

Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.

Flora Affuso, Emiliano Antonio Palmieri, Pasquale Di Conza, Vincenzo Guardasole, Serafino Fazio.   

Abstract

Pulmonary arterial hypertension has a poor prognosis quoad vitam et valitudinem. Herein, we report on a middle-aged woman affected by idiopathic pulmonary arterial hypertension whose quality of life and exercise tolerance improved remarkably after a six-month course of treatment with the long-acting phosphodiesterase-5 inhibitor tadalafil.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260051     DOI: 10.1016/j.ijcard.2005.08.051

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  Long term combination treatment for severe idiopathic pulmonary arterial hypertension.

Authors:  Flora Affuso; Plinio Cirillo; Antonio Ruvolo; Guido Carlomagno; Serafino Fazio
Journal:  World J Cardiol       Date:  2010-03-26

2.  Pulmonary arterial hypertension.

Authors:  Sheng Chin Wu; Sergio Caravita; Elisabetta Lisi; Simona Pierini; Viola Dadone; Sarah E Todd; Francesco Gentile; Maria Beatrice Secchi
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

Review 3.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.

Authors:  Mohammad Reza Sabri; Elham Beheshtian
Journal:  Pediatr Cardiol       Date:  2013-11-20       Impact factor: 1.655

5.  Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.

Authors:  Stuart D Katz
Journal:  Core Evid       Date:  2008-07-31

6.  Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation.

Authors:  Mohammad-Reza Sabri; Ali Zolfi-Gol; Alireza Ahmadi; Shaghayegh Haghjooy-Javanmard
Journal:  Pediatr Cardiol       Date:  2015-07-28       Impact factor: 1.655

Review 7.  A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

Authors:  Samuel L Washington; Alan W Shindel
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

8.  The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Authors:  Ghazwan Butrous
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

Review 9.  Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

Authors:  H Al-Ameri; R A Kloner
Journal:  Int J Impot Res       Date:  2009-04-23       Impact factor: 2.896

Review 10.  Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review.

Authors:  Adam M Henrie; James J Nawarskas; Joe R Anderson
Journal:  Core Evid       Date:  2015-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.